Pyrimidinyl sulfonamides as inhibitors of ack1/tnk2 tyrosine kinase

ABSTRACT

The present disclosure provides anti-cancer compounds and uses thereof, more particularly inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority to U.S. ProvisionalApplication No. 63/065,766, filed Aug. 14, 2020, U.S. ProvisionalApplication No. 63/178,350, filed Apr. 22, 2021, and U.S. ProvisionalApplication No. 63/229,392, filed Aug. 4, 2021, each disclosure of whichis incorporated herein by reference in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with government support under Grant No. CA211447awarded by the National Institutes of Health. The Government has certainrights in the invention.

TECHNICAL FIELD

This disclosure relates to anti-cancer compounds and uses thereof, andmore particularly to inhibitors of ACK1 tyrosine kinase and their use inthe treatment of cancer.

BACKGROUND

ACK1, also known as TNK2, is a non-receptor tyrosine kinase that isexpressed in diverse cell types. It integrates signals from severalimportant ligand-activated receptor tyrosine kinases (RTKs), forexample, EGFR, MerTK, HER2, PDGFR and insulin receptor to initiateintracellular signaling cascades. The ACK1 tyrosine kinase is aberrantlyactivated, amplified or mutated in many types of human cancers includingprostate, breast, pancreatic, ovarian and lung cancers (Mahajan K, etal. ACK1 tyrosine kinase: targeted inhibition to block cancer cellproliferation. Cancer Lett. 2013; 338:185-92). Aberrantly activated ACK1drives cell growth via a number of molecular mechanisms (Mahajan K, etal. Shepherding AKT and androgen receptor by ACK1 tyrosine kinase. J.Cell. Physiol. 2010; 224:327-33). Several recent discoveries underscoreits tumor promoting functions. For example, ACK1 phosphorylates theandrogen receptor, at Tyr267 in its transactivation domain, in anandrogen-independent manner to promote castration resistant prostatecancer (CRPC) growth (Mahajan K, et al. Activated Cdc42-associatedkinase ACK1 promotes prostate cancer progression via androgen receptortyrosine phosphorylation. Proc. Natl. Acad. Sci. USA 2007; 104:8438-43;Mahajan K, et al. ACK1-mediated androgen receptor phosphorylationmodulates radiation resistance in castration-resistant prostate cancer.J. Biol. Chem. 2012; 287(26):22112-22). ACK1 has been shown to promoteprostate tumorigenesis by phosphorylating the WW domain-containingoxidoreductase (Wwox) tumor suppressor (Ageilan R I, et al. WWOX inbiological control and tumorigenesis. J. Cell. Physiol. 2007;212:307-10) on Tyr287 leading to its polyubiquitination and subsequentdegradation (Mahajan K, et al. Activated tyrosine kinase ACK1 promotesprostate tumorigenesis: role of ACK1 in polyubiquitination of tumorsuppressor Wwox. Cancer Res. 2005; 65:10514-23). It has also been shownthat ACK1 phosphorylates and activates the key signaling kinase AKT,which plays important roles in human physiology and disease (Franke T F,et al. The protein kinase encoded by the Akt proto-oncogene is a targetof the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995;81:727-36; Burgering B M, et al. Protein kinase B (c-Akt) inphosphatidylinositol-3-OH kinase signal transduction. Nature 1995;376:599-602; Manning B D, et al. AKT/PKB signaling: navigatingdownstream. Cell 2007; 129:1261-74). When AKT is phosphorylated onTyr176 by ACK1 it functionally participates in the progression of breastcancer by suppressing pro-apoptotic pathways (Mahajan K, et al. ACK1mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation.PloS one 2010; 5:e9646). Conversely knockdown of ACK1 expression bysiRNA suppressed AKT activation in MCF7 breast cancer cell line andincreased expression of pro-apoptotic genes such as Bim and Fas (Id.).ACK1 transgenic mice developed prostatic intraepithelial neoplasia(PINs), indicating that its activation is crucial in tumorigenesis(Id.). Significant evidence in pre-clinical models therefore validatesACK1 as a target for anticancer drugs, and has driven the development ofmany ACK1 inhibitors. Selected examples of ACK1 inhibitors are asfollows:

A series of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines (structures 1a-1c)were found to inhibit ACK1 and the related member of the src kinasefamily Lck (lymphocyte-specific kinase) (DiMauro E F, et al. Discoveryof 4-amino-5,6-biaryl-furo[l2,3-d]pyrimidines as inhibitors of Lck:development of an expedient and divergent synthetic route andpreliminary SAR. Bioorg. Med. Chem. Lett. 2007; 17, 2305-9; Martin M W,et al. Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines aspotent and selective inhibitors of Lck: synthesis, SAR, andpharmacokinetic properties. Bioorg. Med. Chem. Lett. 2007; 17:2299-304).For example, compound 1a potently inhibits both ACK1 and Lck and wasuseful in the development of further compounds for the treatment of Tcell-mediated autoimmune and inflammatory disease as a consequence ofLck inhibition. Compound 1b (AIM-100) was used as a chemical probe forACK1 inhibition, since it was reported to inhibit Lck to a lesser extent(ACK1:Lck 5:1) than 1a (Lck:ACK1 1.8:1). AIM-100 inhibits ACK1 dependentAKT Tyr176 (Mahajan K, et al. ACK1 tyrosine kinase activation correlateswith pancreatic cancer progression. Am. J. Pathol. 2012; 180:1386-93) inpancreatic cancer cells and AR Tyr267 (Mahajan K, et al. Effect of ACK1tyrosine kinase inhibitor on ligand-independent androgen receptoractivity. Prostate 2010; 70:1274-85) phosphorylation. AIM-100 alsoinhibits castration and radioresistant prostate xenograft tumor growthvia inhibition of AR Tyr267 phosphorylation (Mahajan K, et al.ACK1-mediated androgen receptor phosphorylation modulates radiationresistance in castration-resistant prostate cancer. J. Biol. Chem. 2012;287:22112-22). A study of further members of the4-amino-5,6-biaryl-furo[2,3-d]pyrimidine series showed that thedithiolane 1c was an exceptionally potent ACK1 inhibitor (K_(i) 0.3 nM).This compound inhibits the growth of a cell line which is dependent uponACK1 with an IC₅₀ of 5 nM. However, its poor pharmacokinetic properties(attributed to oxidation of both the dithiolane ring and NMe₂) precludeduse in an animal model. A series of pyrazolopyrimidines of type 2 havealso been developed by Amgen as ACK1 inhibitors (Kopecky D J, et al.Identification and optimization ofN3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel classof ACK1 inhibitors. Bioorg. Med. Chem. Lett. 2008; 18:6352-6). Forexample, compound 2 potently inhibits ACK1 in vitro (IC₅₀ 2 nM) and inintact cells, as measured by inhibition of ACK1 autophosphorylation(IC₅₀ 20 nM). Gray and co-workers have identified the ACK1 inhibitor 3,by high throughput kinase profiling of a focused library ofpyrimidine-diazepines (Miduturu C V, et al. High-throughput kinaseprofiling: a more efficient approach toward the discovery of new kinaseinhibitors. Chem. Biol. 2011; 18:868-79). This compound abolishes EGFinduced ACK1 autophosphorylation (Tyr284) in HEK293 cells atconcentrations of 2 μM. It also inhibits A549 lung cancer cell growth at10 μM. A series of imidazopyrazine based ACK1 inhibitors have beendeveloped by Jin and co-workers at OSI/Astellas (Jin M, et al. Discoveryof potent, selective and orally bioavailable imidazo[1,5-a]pyrazinederived ACK1 inhibitors. Bioorg. Med. Chem. Lett. 2013; 23:979-84). Forexample, compound 4 is a potent ACK1 inhibitor orally bioavailable inmouse models and good experimental ADMET properties. It inhibits ACK1mediated phosphorylation of poly-(GT) in an AlphaScreen assay with anIC₅₀ of 110 nM. It potently inhibits ACK1 in a cellular context. InNCI-H1703 human non-small cell lung cancer cells its IC₅₀ for ACK1inhibition is 35 nM as measured by an ELISA assay. In this assay ACK1from the cell lysates is captured on an ELISA plate by ACK1 antibodies.The extent of phosphorylation of ACK1 was determined using anenzyme-linked antibody that recognizes phosphotyrosine residues. Severalpromiscuous kinase inhibitors have been shown to inhibit ACK1. Forexample, the Src/Abl kinase inhibitor bosutinib (Golas J M, et al.SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src andAbl kinases, is a potent antiproliferative agent against chronicmyelogenous leukemia cells in culture and causes regression of K562xenografts in nude mice. Cancer Res. 2003; 63:375-81) inhibits ACK1 withan IC₅₀ of 2.7 nM (Remsing R, et al. Global target profile of the kinaseinhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia2009; 23:477-85). Bosutinib was found to inhibit cell migration andinvasion but not viability in a panel of non-small cell lung cancer(NSCLC) cell lines (Tan D S, et al. Bosutinib inhibits migration andinvasion via ACK1 in KRAS mutant non-small cell lung cancer. Mol. Cancer2014; 13:13). These effects were not seen when ACK1 was knocked-downspecifically in K-Ras mutant cell lines. Dasatinib, another BCR/Abl andSrc family tyrosine kinase inhibitor, inhibits ACK1 with a K_(D) of 6 nM(Carter T A, et al. Inhibition of drug-resistant mutants of ABL, KIT,and EGF receptor kinases. Proc. Natl. Acad. Sci. USA 2005; 102:11011-6).Dasatinib was shown to inhibit both ACK1 autophosphorylation and ARphosphorylation of Tyr-267 in heregulin-stimulated human prostate cancerLNCaP cells with IC₅₀s<5 nM (Liu Y, et al. Dasatinib inhibitssite-specific tyrosine phosphorylation of androgen receptor by ACK1 andSrc kinases. Oncogene 2010; 29:3208-16). Additionally, dasatinibsignificantly reduced the growth of LNCaP cells expressingconstitutively activated ACK1 in a mouse xenograft model (Id.). Chemicaland phosphoproteomic approaches revealed ACK1 to be a target ofdasatinib in human lung cancer cells (Li J, et al. A chemical andphosphoproteomic characterization of dasatinib action in lung cancer.Nat. Chem. Biol. 2010; 6:291-9).

ACK1 inhibitors are developed by analysis of known ACK1 inhibitorsincluding 1b (AIM-100), the pyrazolopyrimidine derivative 5 (Kopecky DJ, et al. Identification and optimization ofN3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel classof ACK1 inhibitors. Bioorg. Med. Chem. Lett. 2008; 18:6352-6) and theALK inhibitor 6 (TAE684) (Galkin A V, et al. Identification ofNVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.Proc. Natl. Acad. Sci. USA 2007; 104:270-5) (which stronglycross-inhibits ACK1 from published inhibitor profiling data sets; K_(d)2 nM (Davis M I, et al. Comprehensive analysis of kinase inhibitorselectivity. Nat. Biotechnol. 2011; 29:1046-51) and K_(i) 1 nM (Metz JT, et al. Navigating the kinome. Nat. Chem. Biol. 2011; 7:200-2)). Thebinding modes of the three inhibitors are shown in FIGS. 1A through 1F,as derived from the X-ray structure of 5 with ACK1 (pdb 3EQR); 1b(AIM-100) modeled from the X-ray structure of an analog with ACK1 (JiaoX, et al. Synthesis and optimization of substitutedfuro[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-aminesas ACK1 inhibitors. Bioorg. Med. Chem. Lett. 2012; 22:6212-7) (pdb4EWH); 6 modeled from its X-ray structure with ALK (Bossi R T, et al.Crystal structures of anaplastic lymphoma kinase in complex with ATPcompetitive inhibitors. Biochem. 2010; 49:6813-25) (pdb 2XB7). Thesebind the ACK1 hinge residues Ala-208 via the pyrimidyl group,positioning groups in the hydrophobic pocket beyond the gatekeeper, andin the ribose binding region (Galkin A V, et al. Identification ofNVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.Proc. Natl. Acad. Sci. USA 2007; 104:270-5). The bisanilinopyrimidinescaffold has been long recognized as a classical kinase inhibitor motif(Bebbington D, et al. The discovery of the potent aurora inhibitorMK-0457 (VX-680). Bioorg. Med. Chem. Lett. 2009; 19:3586-92; Moriarty KJ, et al. The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: anew class of Aurora-A kinase inhibitors. Bioorg. Med. Chem. Lett. 2006;16:5778-83; Tari L W, et al. Structural basis for the inhibition ofAurora A kinase by a novel class of high affinity disubstitutedpyrimidine inhibitors. Bioorg. Med. Chem. Lett. 2007; 17:688-691).Aurora A inhibitors were reported using a bisanilinopyrimidine scaffold(Lawrence H R, et al. Development of o-chlorophenyl substitutedpyrimidines as exceptionally potent aurora kinase inhibitors. J. Med.Chem. 2012; 55:7392-416; Martin M P, et al. A novel mechanism by whichsmall molecule inhibitors induce the DFG flip in Aurora A. ACS Chem.Biol. 2012; 7:698-706; Yang H, et al. Dual Aurora A and JAK2 kinaseblockade effectively suppresses malignant transformation. Oncotarget2014; 5:2947-61). In the development of novel ACK1 inhibitors, thedesign process incorporated an aminopyrimidine structure as the hingebinding group (FIG. 1D) and the fragments of 1b, 5 and 6 as R¹, R² andR³ (FIG. 1D) groups to create hybrid structures in a mix and matchprocess (FIGS. 1A through 1F).

There is a clear need for new compounds and methods for inhibiting ACK1.The present disclosure addresses these needs.

SUMMARY

In accordance with the purposes of the disclosed materials and methods,as embodied and broadly described herein, the disclosed subject matter,in one aspect, relates to compounds, compositions and methods of makingand using compounds and compositions. In specific aspects, the disclosedsubject matter relates to anti-cancer compounds their uses thereof. Morespecifically, the subject matter disclosed herein relates to inhibitorsof ACK1 tyrosine kinase and their use in the treatment of cancer.

Additional advantages will be set forth in part in the description thatfollows, and in part will be obvious from the description, or may belearned by practice of the aspects described below. The advantagesdescribed below will be realized and attained by means of the elementsand combinations particularly pointed out in the appended claims. It isto be understood that both the foregoing general description and thefollowing detailed description are exemplary and explanatory only andare not restrictive.

DETAILED DESCRIPTION

The materials, compounds, compositions, and methods described herein maybe understood more readily by reference to the following detaileddescription of specific aspects of the disclosed subject matter and theExamples included therein.

Before the present materials, compounds, compositions, and methods aredisclosed and described, it is to be understood that the aspectsdescribed below are not limited to specific synthetic methods orspecific reagents, as such may, of course, vary. It is also to beunderstood that the terminology used herein is for the purpose ofdescribing particular aspects only and is not intended to be limiting.

Also, throughout this specification, various publications arereferenced. The disclosures of these publications in their entiretiesare hereby incorporated by reference into this application in order tomore fully describe the state of the art to which the disclosed matterpertains. The references disclosed are also individually andspecifically incorporated by reference herein for the material containedin them that is discussed in the sentence in which the reference isrelied upon.

Definitions

In this specification and in the claims that follow, reference will bemade to a number of terms, which shall be defined to have the followingmeanings:

Throughout the specification and claims the word “comprise” and otherforms of the word, such as “comprising” and “comprises,” means includingbut not limited to, and is not intended to exclude, for example, otheradditives, components, integers, or steps.

As used in the description and the appended claims, the singular forms“a,” “an,” and “the” include plural referents unless the context clearlydictates otherwise. Thus, for example, reference to “a composition”includes mixtures of two or more such compositions, reference to “aninhibitor” includes mixtures of two or more such inhibitors, referenceto “the kinase” includes mixtures of two or more such kinase, and thelike.

“Optional” or “optionally” means that the subsequently described eventor circumstance can or cannot occur, and that the description includesinstances where the event or circumstance occurs and instances where itdoes not.

Notwithstanding that the numerical ranges and parameters setting forththe broad scope of the disclosure are approximations, the numericalvalues set forth in the specific examples are reported as precisely aspossible. Any numerical value, however, inherently contain certainerrors necessarily resulting from the standard deviation found in theirrespective testing measurements. Furthermore, when numerical ranges ofvarying scope are set forth herein, it is contemplated that anycombination of these values inclusive of the recited values may be used.Further, ranges can be expressed herein as from “about” one particularvalue, and/or to “about” another particular value. When such a range isexpressed, another aspect includes from the one particular value and/orto the other particular value. Similarly, when values are expressed asapproximations, by use of the antecedent “about,” it will be understoodthat the particular value forms another aspect. It will be furtherunderstood that the endpoints of each of the ranges are significant bothin relation to the other endpoint, and independently of the otherendpoint. Unless stated otherwise, the term “about” means within 5%(e.g., within 2% or 1%) of the particular value modified by the term“about.”

By “reduce” or other forms of the word, such as “reducing” or“reduction,” is meant lowering of an event or characteristic (e.g.,tumor growth, metastasis). It is understood that this is typically inrelation to some standard or expected value, in other words it isrelative, but that it is not always necessary for the standard orrelative value to be referred to. For example, “reduces tumor growth”means decreasing the amount of tumor cells relative to a standard or acontrol.

By “prevent” or other forms of the word, such as “preventing” or“prevention,” is meant to stop a particular event or characteristic, tostabilize or delay the development or progression of a particular eventor characteristic, or to minimize the chances that a particular event orcharacteristic will occur. Prevent does not require comparison to acontrol as it is typically more absolute than, for example, reduce. Asused herein, something could be reduced but not prevented, but somethingthat is reduced could also be prevented. Likewise, something could beprevented but not reduced, but something that is prevented could also bereduced. It is understood that where reduce or prevent are used, unlessspecifically indicated otherwise, the use of the other word is alsoexpressly disclosed.

As used herein, “treatment” refers to obtaining beneficial or desiredclinical results. Beneficial or desired clinical results include, butare not limited to, any one or more of: alleviation of one or moresymptoms (such as tumor growth or metastasis), diminishment of extent ofcancer, stabilized (i.e., not worsening) state of cancer, preventing ordelaying spread (e.g., metastasis) of the cancer, preventing or delayingoccurrence or recurrence of cancer, delay or slowing of cancerprogression, amelioration of the cancer state, and remission (whetherpartial or total).

The term “patient” preferably refers to a human in need of treatmentwith an anti-cancer agent or treatment for any purpose, and morepreferably a human in need of such a treatment to treat cancer, or aprecancerous condition or lesion. However, the term “patient” can alsorefer to non-human animals, preferably mammals such as dogs, cats,horses, cows, pigs, sheep and non-human primates, among others, that arein need of treatment with an anti-cancer agent or treatment.

It is understood that throughout this specification the identifiers“first” and “second” are used solely to aid in distinguishing thevarious components and steps of the disclosed subject matter. Theidentifiers “first” and “second” are not intended to imply anyparticular order, amount, preference, or importance to the components orsteps modified by these terms.

As used herein, the term “composition” is intended to encompass aproduct comprising the specified ingredients in the specified amounts,as well as any product which results, directly or indirectly, fromcombination of the specified ingredients in the specified amounts.

References in the specification and concluding claims to parts by weightof a particular element or component in a composition denotes the weightrelationship between the element or component and any other elements orcomponents in the composition or article for which a part by weight isexpressed. Thus, in a mixture containing 2 parts by weight of componentX and 5 parts by weight component Y, X and Y are present at a weightratio of 2:5, and are present in such ratio regardless of whetheradditional components are contained in the mixture.

A weight percent (wt. %) of a component, unless specifically stated tothe contrary, is based on the total weight of the formulation orcomposition in which the component is included.

It is to be understood that the compounds provided herein may containchiral centers. Such chiral centers may be of either the (R-) or (S-)configuration. The compounds provided herein may either beenantiomerically pure, or be diastereomeric or enantiomeric mixtures. Itis to be understood that the chiral centers of the compounds providedherein may undergo epimerization in vivo. As such, one of skill in theart will recognize that administration of a compound in its (R-) form isequivalent, for compounds that undergo epimerization in vivo, toadministration of the compound in its (S-) form.

As used herein, substantially pure means sufficiently homogeneous toappear free of readily detectable impurities as determined by standardmethods of analysis, such as thin layer chromatography (TLC), nuclearmagnetic resonance (NMR), gel electrophoresis, high performance liquidchromatography (HPLC) and mass spectrometry (MS), gas-chromatographymass spectrometry (GC-MS), and similar, used by those of skill in theart to assess such purity, or sufficiently pure such that furtherpurification would not detectably alter the physical and chemicalproperties, such as enzymatic and biological activities, of thesubstance. Both traditional and modern methods for purification of thecompounds to produce substantially chemically pure compounds are knownto those of skill in the art. A substantially chemically pure compoundmay, however, be a mixture of stereoisomers.

Unless stated to the contrary, a formula with chemical bonds shown onlyas solid lines and not as wedges or dashed lines contemplates eachpossible isomer, e.g., each enantiomer, diastereomer, and meso compound,and a mixture of isomers, such as a racemic or scalemic mixture.

A dash (“-”) that is not between two letters or symbols is used toindicate a point of attachment for a substituent. For example, —(C═O)NH₂is attached through the carbon of the keto (C═O) group.

The term “substituted”, as used herein, means that any one or morehydrogens on the designated atom or group is replaced with a moietyselected from the indicated group, provided that the designated atom'snormal valence is not exceeded and the resulting compound is stable. Forexample, when the substituent is oxo (i.e., ═O) then two hydrogens onthe atom are replaced. For example, a pyridyl group substituted by oxois a pyridine. Combinations of substituents and/or variables arepermissible only if such combinations result in stable compounds oruseful synthetic intermediates. A stable active compound refers to acompound that can be isolated and can be formulated into a dosage formwith a shelf life of at least one month. A stable manufacturingintermediate or precursor to an active compound is stable if it does notdegrade within the period needed for reaction or other use. A stablemoiety or substituent group is one that does not degrade, react or fallapart within the period necessary for use. Non-limiting examples ofunstable moieties are those that combine heteroatoms in an unstablearrangement, as typically known and identifiable to those of skill inthe art.

Any suitable group may be present on a “substituted” or “optionallysubstituted” position that forms a stable molecule and meets the desiredpurpose of the invention and includes, but is not limited to: alkyl,haloalkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl,heterocycle, aldehyde, amino, carboxylic acid, ester, ether, halo,hydroxy, keto, nitro, cyano, azido, oxo, silyl, sulfo-oxo, sulfonyl,sulfone, sulfoxide, sulfonylamino, or thiol.

“Alkyl” is a straight chain or branched saturated aliphatic hydrocarbongroup. In certain embodiments, the alkyl is C₁-C₂, C₁-C₃, or C₁-C₆(i.e., the alkyl chain can be 1, 2, 3, 4, 5, or 6 carbons in length).The specified ranges as used herein indicate an alkyl group with lengthof each member of the range described as an independent species. Forexample, C₁-C₆alkyl as used herein indicates an alkyl group having from1, 2, 3, 4, 5, or 6 carbon atoms and is intended to mean that each ofthese is described as an independent species and C₁-C₄alkyl as usedherein indicates an alkyl group having from 1, 2, 3, or 4 carbon atomsand is intended to mean that each of these is described as anindependent species. When C₀-C_(n)alkyl is used herein in conjunctionwith another group, for example (C₃-C₇cycloalkyl)C₀-C₄alkyl, or—C₀-C₄(C₃-C₇cycloalkyl), the indicated group, in this case cycloalkyl,is either directly bound by a single covalent bond (C₀alkyl), orattached by an alkyl chain, in this case 1, 2, 3, or 4 carbon atoms.Alkyls can also be attached via other groups such as heteroatoms, as in—O—C₀-C₄alkyl(C₃-C₇cycloalkyl). Examples of alkyl include, but are notlimited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,sec-butyl, t-butyl, n-pentyl, isopentyl, tert-pentyl, neopentyl,n-hexyl, 2-methylpentane, 3-methylpentane, 2,2-dimethylbutane, and2,3-dimethylbutane. In one embodiments, the alkyl group is optionallysubstituted as described herein.

“Cycloalkyl” is a saturated mono- or multi-cyclic hydrocarbon ringsystem. When composed of two or more rings, the rings may be joinedtogether in a fused or bridged fashion. Non-limiting examples of typicalcycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, and cycloheptyl. In one embodiment, the cycloalkyl group isoptionally substituted as described herein.

“Alkoxy” is an alkyl group as defined above covalently bound through anoxygen bridge (—O—). Examples of alkoxy include, but are not limited to,methoxy, ethoy, n-propoxy, isopropoxy, n-butoxy, 2-butoxy, tert-butoxy,n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, n-hexoxy,2-hexoxy, 3-hexoxy, and 3-methylpentoxy. Similarly, an “alkylthio” or“thioalkyl” group is an alkyl group as defined above with the indicatednumber of carbon atoms covalently bound through a sulfur bridge (—S—).In one embodiment, the alkoxy group is optionally substituted asdescribed herein.

“Alkanoyl” is an alkyl group as defined above covalently bound through acarbonyl (C═O) bridge. The carbonyl carbon is included in the number ofcarbons, for example C₂alkanoyl is a CH₃(C═O)— group. In one embodiment,the alkanoyl group is optionally substituted as described herein.

“Halo” or “halogen” indicates, independently, any of fluoro, chloro,bromo or iodo.

The term “heterocycle” refers to saturated and partially saturatedheteroatom-containing ring radicals, where the heteroatoms may beselected from N, O, and S. The term heterocycle includes monocyclic 3-12members rings, as well as bicyclic 5-16 membered ring systems (which caninclude fused, bridged, or spiro bicyclic ring systems). It does notinclude rings containing —O—O—, —O—S—, and —S—S— portions. Examples ofsaturated heterocycle groups including saturated 4- to 7-memberedmonocyclic groups containing 1 to 4 nitrogen atoms [e.g., pyrrolidinyl,imidazolidinyl, piperidinyl, pyrrolinyl, azetidinyl, piperazinyl, andpyrazolidinyl]; saturated 4- to 6-membered monocyclic groups containing1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g., morpholinyl]; andsaturated 3- to 6-membered heteromonocyclic groups containing 1 to 2sulfur atoms and 1 to 3 nitrogen atoms [e.g., thiazolidinyl]. Examplesof partially saturated heterocycle radicals include, but are notlimited, dihydrothienyl, dihydropyranyl, dihydrofuryl, anddihydrothiazolyl. Examples of partially saturated and saturatedheterocycle groups include, but are not limited to, pyrrolidinyl,imidazolidinyl, piperidinyl, pyrrolinyl, pyrazolidinyl, piperazinyl,morpholinyl, tetrahydropyranyl, thiazolidinyl, dihydrothienyl,2,3-dihydro-benzo[1,4]dioxanyl, indolinyl, isoindolinyl,dihydrobenzothienyl, dihydrobenzofuryl, isochromanyl, chromanyl,1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl,1,2,3,4-tetrahydro-quinolyl, 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl,5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolyl,3,4-dihydro-2H-benzo[1,4]oxazinyl, benzo[1,4]dioxanyl,2,3,-dihydro-1H-benzo[d]isothazol-6-yl, dihydropyranyl, dihydrofuryl,and dihydrothiazolyl. Bicyclic heterocycle includes groups wherein theheterocyclic radical is fused with an aryl radical wherein the point ofattachment is the heterocycle ring. Bicyclic heterocycle also includesheterocyclic radicals that are fused with a carbocyclic radical.Representative examples include, but are not limited to, partiallyunsaturated condensed heterocyclic groups containing 1 to 5 nitrogenatoms, for example indoline and isoindoline, partially unsaturatedcondensed heterocyclic groups containing 1 to 2 oxygen atoms and 1 to 3nitrogen atoms, partially unsaturated condensed heterocyclic groupscontaining 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, and saturatedcondensed heterocyclic groups containing 1 to 2 oxygen or sulfur atoms.

“Heteroaryl” refers to a stable monocyclic, bicyclic, or multicyclicaromatic ring which contains from 1 to 3, or in some embodiments 1, 2,or 3 heteroatoms selected from N, O, S, B, and P (and typically selectedfrom N, O, and S) with remaining ring atoms being carbon, or a stablebicyclic or tricyclic system containing at least one 5, 6, or 7 memberedaromatic ring which contains from 1 to 3, or in some embodiments from 1to 2, heteroatoms selected from N, O, S, B, or P, with remaining ringatoms being carbon. In one embodiments, the only heteroatom is nitrogen.In one embodiment, the only heteroatom is oxygen. In one embodiment, theonly heteroatom is sulfur. Monocyclic heteroaryl groups typically havefrom 5 to 6 ring atoms. In some embodiments, bicyclic heteroaryl groupsare 8- to 10-membered heteroaryl groups, that is groups containing 8 or10 ring atoms in which one 5-, 6-, or 7-membered aromatic ring is fusedto a second aromatic or non-aromatic ring, wherein the point ofattachment is the aromatic ring. When the total number of S and O atomsin the heteroaryl group excess 1, these heteroatoms are not adjacent toone another. In one embodiment, the total number of S and O atoms in theheteroaryl group is not more than 2. In another embodiment, the totalnumber of S and O atoms in the heteroaryl group is not more than 1.Examples of heteroaryl groups include, but are not limited to,pyridinyl, imidazolyl, imidazopyridinyl, pyrimidinyl, pyrazolyl,triazolyl, pyrazinyl, furyl, thienyl, isoxazolyl, thiazolyl,oxadiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl,isoquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl,benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl,pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, triazolyl,thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl,benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl,naphthyridinyl, and furopyridinyl.

A “pharmaceutically acceptable” component is one that is suitable foruse with humans and/or animals without undue adverse side effects (suchas toxicity, irritation, and allergic response) commensurate with areasonable benefit/risk ratio.

“Pharmaceutically acceptable salt” refers to a salt that ispharmaceutically acceptable and has the desired pharmacologicalproperties. Such salts include those that may be formed where acidicprotons present in the compounds are capable of reacting with inorganicor organic bases. Suitable inorganic salts include those formed with thealkali metals, e.g., sodium, potassium, magnesium, calcium, andaluminum. Suitable organic salts include those formed with organic basessuch as the amine bases, e.g., ethanolamine, diethanolamine,triethanolamine, tromethamine, N-methylglucamine, and the like. Suchsalts also include acid addition salts formed with inorganic acids(e.g., hydrochloric and hydrobromic acids) and organic acids (e.g.,acetic acid, citric acid, maleic acid, and the alkane- andarene-sulfonic acids such as methanesulfonic acid and benzenesulfonicacid). When two acidic groups are present, a pharmaceutically acceptablesalt may be a mono-acid-mono-salt or a di-salt; similarly, where thereare more than two acidic groups present, some or all of such groups canbe converted into salts.

“Pharmaceutically acceptable excipient” refers to an excipient that isconventionally useful in preparing a pharmaceutical composition that isgenerally safe, non-toxic, and desirable, and includes excipients thatare acceptable for veterinary use as well as for human pharmaceuticaluse. Such excipients can be solid, liquid, semisolid, or, in the case ofan aerosol composition, gaseous.

A “pharmaceutically acceptable carrier” is a carrier, such as a solvent,suspending agent or vehicle, for delivering the disclosed compounds tothe patient. The carrier can be liquid or solid and is selected with theplanned manner of administration in mind. Liposomes are also apharmaceutical carrier. As used herein, “carrier” includes any and allsolvents, dispersion media, vehicles, coatings, diluents, antibacterialand antifungal agents, isotonic and absorption delaying agents, buffers,carrier solutions, suspensions, colloids, and the like. The use of suchmedia and agents for pharmaceutical active substances is well known inthe art. Except insofar as any conventional media or agent isincompatible with the active ingredient, its use in the therapeuticcompositions is contemplated.

The term “therapeutically effective amount” as used herein means thatamount of active compound or pharmaceutical agent that elicits thebiological or medicinal response in a tissue, system, animal or humanthat is being sought by a researcher, veterinarian, medical doctor orother clinician. In reference to cancers or other unwanted cellproliferation, an effective amount comprises an amount sufficient tocause a tumor to shrink and/or to decrease the growth rate of the tumor(such as to suppress tumor growth) or to prevent or delay other unwantedcell proliferation. In some embodiments, an effective amount is anamount sufficient to delay development. In some embodiments, aneffective amount is an amount sufficient to prevent or delay occurrenceand/or recurrence. An effective amount can be administered in one ormore doses. In the case of cancer, the effective amount of the drug orcomposition may: (i) reduce the number of cancer cells; (ii) reducetumor size; (iii) inhibit, retard, slow to some extent and preferablystop cancer cell infiltration into peripheral organs; (iv) inhibit(i.e., slow to some extent and preferably stop) tumor metastasis; (v)inhibit tumor growth; (vi) prevent or delay occurrence and/or recurrenceof tumor; and/or (vii) relieve to some extent one or more of thesymptoms associated with the cancer.

Effective amounts of a compound or composition described herein fortreating a mammalian subject can include about 0.1 to about 1000 mg/Kgof body weight of the subject/day, such as from about 1 to about 100mg/Kg/day, especially from about 10 to about 100 mg/Kg/day. The dosescan be acute or chronic. A broad range of disclosed composition dosagesare believed to be both safe and effective.

Reference will now be made in detail to specific aspects of thedisclosed materials, compounds, compositions, articles, and methods,examples of which are illustrated in the accompanying Examples.

Compounds

The present disclosure provides compounds that are ACK1 tyrosine kinaseinhibitors. These disclosed compounds can be used in variouscompositions as anti-cancer Therapeutics.

In one aspect, a compound is provided of Formula I:

-   -   or a pharmaceutically acceptable salt thereof;    -   wherein:    -   R¹ is selected from C₁-C₆ alkyl, C₃-C₆ cycloalkyl, and aryl;    -   R² is selected from hydrogen and halo;    -   R³ is selected from C₁-C₆ alkyl and halo;    -   R⁴ is selected from C₁-C₆ alkoxy, aryloxy, and C₃-C₆        cycloalkyoxy;    -   R⁵ is C₁-C₆ alkoxy, C₃-C₆ cycloalkoxy, C₁-C₆ alkyl, halo, cyano,        and hydroxy;    -   L is selected from a bond, C₁-C₃ alkyl, or —O—(C₁-C₃ alkyl)-;    -   R⁶ is selected from optionally substituted C₄-C₈ heterocycle or        optionally substituted heteroaryl; and    -   m is 0 or 1.

In another aspect, a compound of Formula II is provided:

-   -   or a pharmaceutically acceptable salt thereof;    -   wherein:    -   R¹ is selected from C₁-C₆ alkyl, C₃-C₆ cycloalkyl, and aryl;    -   R³ is selected from C₁-C₆ alkyl and halo;    -   L is selected from a bond, C₁-C₃ alkyl, or —O—(C₁-C₃ alkyl)-;    -   R⁶ is selected from optionally substituted C₄-C₈ heterocycle or        optionally substituted heteroaryl;    -   R⁷ is selected from C₁-C₆ alkoxy, C₃-C₆ cycloalkoxy, C₁-C₆        alkyl, halo, cyano, and hydroxy; and    -   n is 0, 1, or 2.

In some embodiments of Formula I or Formula II, R¹ is methyl. In someembodiments of Formula I or Formula II, R¹ is ethyl. In some embodimentsof Formula I or Formula II, R¹ is n-propyl. In some embodiments ofFormula I or Formula II, R¹ is isopropyl. In some embodiments of FormulaI or Formula II, R¹ is t-butyl.

In some embodiments of Formula I, R² is hydrogen. In some embodiments ofFormula I, R² is halo. In some embodiments of Formula I, R² is chloro.In some embodiments of Formula I, R² is fluoro.

In some embodiments of Formula I or Formula II, R³ is C₁-C₆ alkyl. Insome embodiments of Formula I or Formula II, R³ is methyl. In someembodiments of Formula I or Formula II, R³ is halo. In some embodimentsof Formula I or Formula II, R³ is chloro. In some embodiments of FormulaI or Formula II, R³ is fluoro.

In some embodiments of Formula I, R⁴ is methoxy. In some embodiments ofFormula I, R⁴ is ethoxy. In some embodiments of Formula I, R⁴ isisopropyloxy. In some embodiments of Formula I, R⁴ is cyclopropyloxy. Insome embodiments of Formula I, R⁴ is cyclobutyloxy. In some embodimentsof Formula I, R⁴ is cyclopentyloxy.

In some embodiments of Formula I, m is 0. In some embodiments of FormulaI, m is 1.

In some embodiments of Formula I, R⁵ is chloro. In some embodiments ofFormula I, R⁵ is fluoro.

In some embodiments of Formula I or Formula II, L is a bond. In someembodiments of Formula I or Formula II, L is —CH₂—. In some embodimentsof Formula I or Formula II, L is —O—CH₂—. In some embodiments of FormulaI or Formula II, L is —O—CH₂CH₂—.

In some embodiments of Formula I or Formula II R⁶ is selected from:

In some embodiments of Formula II, n is 0. In some embodiments ofFormula II, n is 1. In some embodiments of Formula II n is 2.

In some embodiments of Formula II, R⁷ is methoxy. In some embodiments ofFormula II, R⁷ is ethoxy. In some embodiments of Formula II, R⁷ isisopropyloxy. In some embodiments of Formula II, R⁷ is cyclopropyloxy.In some embodiments of Formula II, R⁷ is cyclobutyloxy. In someembodiments of Formula II, R⁷ is cyclopentyloxy. In some embodiments ofFormula II, R⁷ is chloro. In some embodiments of Formula II, R⁷ isfluoro.

In another aspect, a compound is provided selected from the list ofcompounds provided in Table 1:

TABLE 1 ACK1 Inhibitors ACK1 Compound #, ELISA % Chemical Structure,ACK1 Inhibition Name IC₅₀ at 100 nM

33.2 nM 98.7 N-(2-chloro-5-((2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2- methylpropane-2-sulfonamide

34.5 nM 100.3 N-(3-((2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2- methylpropane-2-sulfonamide

In another aspect, a compound is provided selected from the list ofcompounds provided in Table 2:

TABLE 2 Further ACK1 Inhibitors Compound #, ACK1 IC₅₀ (nM) ChemicalStructure, (Reaction Biology Cell viability Name ³³P Hotspot assay) EC50

13; 13.8 0.47 uM (UKE1) 213 nM (MDA- MB-231)N-(3-((2-((3-isopropoxy-4-(4- methylpiperazin-1- yl)phenyl)amino)-5-methylpyrimidin-4- yl)amino)phenyl)-2- methylpropane-2-sulfonamide

21.9 BRD4 (RB) 588 nM BRD4 MA2- 014 (RB) 39.2 nM BRD4 JQ1 (RB) 27.8 nMN-(3-((2-((2-methoxy-4-(4- mehtylpiperazin-1- yl)phenyl)amino)-5-methylpyrimidin-4- yl)amino)phenyl)-2- methylpropane-2-sulfonamide

26 N-(3-((2-((3-isopropoxy-4-(1- methyl-1H-pyrazol-4-yl)phenyl)amino)-5- methylpyrimidin-4- yl)amino)phenyl)-2-methylpropane-2-sulfonamide

In another aspect, a compound is provided selected from the list ofcompounds provided in Table 3:

TABLE 3 Further ACK1 Inhibitors Compound #, ACK1 IC₅₀ (nM) ChemicalStructure, (Reaction Biology ³³P Cell viability Name Hotspot assay) EC50

14 0.85 uM (UKE1) 220 nM (MDA-MB- 231)N-(2-chloro-5-((2-((3-isopropoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2- methylpropane-2-sulfonamide

17 0.35 uM (UKE1) 88.4 nM (MDA-MB- 231) N-(3-((2-((3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2- methylpropane-2-sulfonamide

19.8 >10 uM (UKE1) 11.05 uM (MDA-MB- 231)N-(3-((2-((2-methoxy-4-(1H-pyrazol-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2-methylpropane-2- sulfonamide

26.2 N-(3-((2-((2-cyclobutoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2- methylpropane-2-sulfonamide

15.2 N-(3-((2-((2-methoxy-4-(1-methyl-1H- pyrazol-4-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2- methylpropane-2-sulfonamide

26 2-methyl-N-(3-((5-methyl-2-((4- ((tetrahydro-2H-pyran-4-yl)methoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)propane-2-sulfonamide

15 N-(3-((5-chloro-2-((3-isopropoxy-4-(4- methylpiperazin-1-yl)phenyl)amino)pyrimidin-4- yl)amino)phenyl)-2-methylpropane-2-sulfonamide

30 N-(3-((5-chloro-2-((2-cyclobutoxy-4-(4- methylpiperazin-1-yl)phenyl)amino)pyrimidin-4- yl)amino)phenyl)-2-methylpropane-2-sulfonamide

64 N-(3-((5-chloro-2-((3-isopropoxy-4-(1- methyl-1H-pyrazol-4-yl)phenyl)amino)pyrimidin-4- yl)amino)phenyl)-2-methylpropane-2-sulfonamide

19 N-(3-((2-((3-methoxy-4-(1-methyl-1H- pyrazol-4-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2- methylpropane-2-sulfonamide

149 N-(3-((2-((2-isopropoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-5- methylpyrimidin-4-yl)amino)phenyl)-2-methylpropane-2-sulfonamide

37.6 N-(3-((2-((3-fluoro-2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2- methylpropane-2-sulfonamide

16.9 N-(3-((2-((5-fluoro-2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2- methylpropane-2-sulfonamide

15.3 N-(3-((2-((4-(4-acetylpiperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2-methylpropane-2- sulfonamide

21.3 N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2- methoxyphenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2- methylpropane-2-sulfonamide

7.62 N-(4-((2-((2-methoxy-4-(4- methylpiperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2- methylpropane-2-sulfonamide

13 N-(3-((2-((4-(4-acetylpiperazin-1-yl)-3- isopropoxyphenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2- methylpropane-2-sulfonamide

18.7 N-(4-((2-((3-isopropoxy-4-(4- methylpiperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2- methylpropane-2-sulfonamide

15.9 N-(4-((2-((3-methoxy-4-(4- methylpiperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2- methylpropane-2-sulfonamide

16.9 N-(4-((2-((3-isopropoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-5- methylpyrimidin-4-yl)amino)phenyl)-2-methylpropane-2-sulfonamide

17.5 N-(4-((5-chloro-2-((2-methoxy-4-(4- methylpiperazin-1-yl)phenyl)amino)pyrimidin-4- yl)amino)phenyl)-2-methylpropane-2-sulfonamide

15.5 N-(4-((5-chloro-2-((3-isopropoxy-4-(4- methylpiperazin-1-yl)phenyl)amino)pyrimidin-4- yl)amino)phenyl)-2-methylpropane-2-sulfonamide

26.7 N-(4-((5-chloro-2-((3-isopropoxy-4-(4- methylpiperazin-1-yl)phenyl)amino)pyrimidin-4- yl)amino)phenyl)methanesulfonamide

17.5 N-(4-((5-chloro-2-((3-methoxy-4-(4- methylpiperazin-1-yl)phenyl)amino)pyrimidin-4- yl)amino)phenyl)-2-methylpropane-2-sulfonamide

75.9 N-(4-((5-chloro-2-((3-isopropoxy-4-(1- methyl-1H-pyrazol-4-yl)phenyl)amino)pyrimidin-4- yl)amino)phenyl)-2-methylpropane-2-sulfonamide

30.8 N-(4-((2-((5-fluoro-2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-2- methylpropane-2-sulfonamide

14.8 N-(4-((2-((5-fluoro-2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5- methylpyrimidin-4-yl)amino)phenyl)methanesulfonamide

26 N-(4-((5-chloro-2-((2-methoxy-2-(4- methylpiperazin-1-yl)phenyl)amino)pyrimidin-4- yl)amino)phenyl)methanesulfonamide

The disclosed compounds can also exist as pharmaceutically acceptablesalts and examples of such salts are disclosed herein.

Methods of Use

Further provided herein are methods of treating or preventing cancer ina subject, comprising administering to the subject an effective amountof a compound or composition as disclosed herein. The methods canfurther comprise administering a second compound or composition, suchas, for example, anticancer agents or anti-inflammatory agents.Additionally, the method can further comprise administering an effectiveamount of ionizing radiation to the subject.

Methods of killing a tumor cell are also provided herein. The methodscomprise contacting a tumor cell with an effective amount of a compoundor composition as disclosed herein. The methods can further includeadministering a second compound or composition (e.g., an anticanceragent or an anti-inflammatory agent) or administering an effectiveamount of ionizing radiation to the subject.

Also provided herein are methods of radiotherapy of tumors, comprisingcontacting the tumor with an effective amount of a compound orcomposition as disclosed herein and irradiating the tumor with aneffective amount of ionizing radiation.

Also disclosed are methods for treating oncological disorders in apatient. In one embodiment, an effective amount of one or more compoundsor compositions disclosed herein is administered to a patient having anoncological disorder and who is in need of treatment thereof. Thedisclosed methods can optionally include identifying a patient who is orcan be in need of treatment of an oncological disorder. The patient canbe a human or other mammal, such as a primate (monkey, chimpanzee, ape,etc.), dog, cat, cow, pig, or horse, or other animals having anoncological disorder. Oncological disorders include, but are not limitedto, cancer and/or tumors of the anus, bile duct, bladder, bone, bonemarrow, bowel (including colon and rectum), breast, eye, gall bladder,kidney, mouth, larynx, esophagus, stomach, testis, cervix, head, neck,ovary, lung, mesothelioma, neuroendocrine, penis, skin, spinal cord,thyroid, vagina, vulva, uterus, liver, muscle, pancreas, prostate, bloodcells (including lymphocytes and other immune system cells), and brain.Specific cancers contemplated for treatment include carcinomas,Karposi's sarcoma, melanoma, mesothelioma, soft tissue sarcoma,pancreatic cancer, lung cancer, leukemia (acute lymphoblastic, acutemyeloid, chronic lymphocytic, chronic myeloid, and other), and lymphoma(Hodgkin's and non-Hodgkin's), and multiple myeloma.

Other examples of cancers that can be treated according to the methodsdisclosed herein are adrenocortical carcinoma, adrenocortical carcinoma,cerebellar astrocytoma, basal cell carcinoma, bile duct cancer, bladdercancer, bone cancer, brain tumor, breast cancer, Burkitt's lymphoma,carcinoid tumor, central nervous system lymphoma, cervical cancer,chronic myeloproliferative disorders, colon cancer, cutaneous T-celllymphoma, endometrial cancer, ependymoma, esophageal cancer, gallbladdercancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, germcell tumor, glioma, hairy cell leukemia, head and neck cancer,hepatocellular (liver) cancer, hypopharyngeal cancer, hypothalamic andvisual pathway glioma, intraocular melanoma, retinoblastoma, islet cellcarcinoma (endocrine pancreas), laryngeal cancer, lip and oral cavitycancer, liver cancer, medulloblastoma, Merkel cell carcinoma, squamousneck cancer with occult mycosis fungoides, myelodysplastic syndromes,myelogenous leukemia, nasal cavity and paranasal sinus cancer,nasopharyngeal cancer, neuroblastoma, non-small cell lung cancer, oralcancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreaticcancer, paranasal sinus and nasal cavity cancer, parathyroid cancer,penile cancer, pheochromocytoma, pineoblastoma and supratentorialprimitive neuroectodermal tumor, pituitary tumor, plasma cellneoplasm/multiple myeloma, pleuropulmonary blastoma, prostate cancer,rectal cancer, renal cell (kidney) cancer, retinoblastoma,rhabdomyosarcoma, salivary gland cancer, Ewing's sarcoma, soft tissuesarcoma, Sezary syndrome, skin cancer, small cell lung cancer, smallintestine cancer, supratentorial primitive neuroectodermal tumors,testicular cancer, thymic carcinoma, thymoma, thyroid cancer,transitional cell cancer of the renal pelvis and ureter, trophoblastictumor, urethral cancer, uterine cancer, vaginal cancer, vulvar cancer,Waldenström's macroglobulinemia, and Wilms' tumor.

In some aspect, disclosed are methods for treating a tumor or tumormetastases in a subject by the administration to the subject acombination of at least one compound or composition as disclosed hereinand at least one cancer immunotherapeutic agent. The disclosed compoundscan be administered alone or in combination with a cancerimmunotherapeutic agent. The subject can receive the therapeuticcompositions prior to, during or after surgical intervention to removeall or part of a tumor. Administration may be accomplished via directimmersion; systemic or localized intravenous (i.v.), intraperitoneal(i.p.), subcutaneous (s.c.), intramuscular (i.m.), or direct injectioninto a tumor mass; and/or by oral administration of the appropriateformulations.

A cancer immunotherapeutic agent suitable for use in the methodsdisclosed herein is an immunotherapeutic agent which comprises a celleffector component joined to a tumor associated antigen targetingcomponent. Suitable cell effector components can include cytotoxicchemicals, cytotoxic radioisotopes, and cell signaling agents such ascytokines. Suitable tumor targeting components are polypeptide chainswhich bind to tumor associated antigens present on or in the surroundingtissue matrix of a tumor cell such as receptor protein chains orimmunoglobulin chains.

Tumor associated antigens which can be used for targets of theimmunotherapeutic agents include a tumor associated antigen selectedfrom the group consisting of AFP, CA 125, CEA, CD19, CD20, CD44, CD45,EGF Receptor, GD[2], GD[3], GM1, GM2, Her-2/Neu, Ep-CAM (KSA), IL-2receptor, Lewis-Y, Lewis-X (CD 15), melanoma-associated proteoglycanMCSP, PSA and Transferrin Receptor.

Examples of immunotherapeutic agents have an effector component that isa cytokine polypeptide joined to a targeting component which is animmunoglobulin (Ig) polypeptide chain. The Ig polypeptide chaincomprises a variable region which binds to a tumor associated antigen.It is preferred that said immunoglobulin chain, when combined with theappropriate complementary chain (i.e. a heavy chain complements a lightchain) defines an antibody active site which is specific for a tumorassociated antigen.

The tumor targeting Ig portion of the immunotherapeutic agent cancomprise an entire immunoglobulin chain amino acid sequence, or at leastthe fragment of which comprises the antigen binding specificity portionof the protein. Thus, a suitable Ig polypeptide chain will have at leastan Ig variable region specific for a tumor associated antigen.

An antibody and polypeptide chains therefrom, suitable for use in thedisclosed methods, will have an amino acid sequence that can be of anymammalian origin. Where such antibody protein is not of the same originas the anticipated patient, fragments of the antibody protein, such asF(ab′)2, Fab, Fv or engineered Fv single chain antibody protein can beused. To further reduce antigenicity of the antibody protein,modification of the antibody amino acid sequence may be accomplished toreduce such by making the protein appear more like the patient's normalantibody components. For example, monoclonal murine antibody amino acidsequences can be modified to appear more human, for administration tohuman patients by a variety of processes for humanization of theantibody.

Specific examples of cancer immunotherapeutic agents include an antibodythat specifically binds CLTA-4, such as ipilimumab (Bristol-MyersSquibb), anti-PD-1, anti-PDL1. Other immunotherapeutic agents includethe TNFα antagonists (e.g. etanercept), the B cell depleting agentrituximab, the anti-IL-6 receptor tocilizumab, and the costimulationblocker abatacept can be administered with the compounds or compositionsdisclosed herein.

The disclosed compounds can also be administered with toll like receptor(TLR) agonist. TLR agonist is a ligand for a TLR selected from the groupconsisting of TLR1, TLR2, TLR3, TLR4, and TLR9. For example, the TLRagonist can be a ligand selected from the group consisting of Pam3CSK4,Pam3CSK4, poly I:C, Ribomunyl, and CpG ODN.

The disclosed compounds can also be administered with an angiogenesisinhibiting agent, which is one which can inhibit the formation of newblood vessels (neovascularization) or enlargement of existing capillarynetworks into the tissues near a tumor cell. Suitable angiogenesisinhibiting agents can be peptides with angiogenesis inhibiting activity,such as the tumor associated antigen PSA. Other suitable angiogenesisinhibiting agents can be antagonists of VEGF associated angiogenesis,for example antagonists of the VEGF receptor on the surface of cells.One monoclonal antibody which can be used is LM609 (ATCC HB 9537).

Methods of Administration

The disclosed compounds can be administered either sequentially orsimultaneously in separate or combined pharmaceutical formulations. Whenone or more of the disclosed compounds is used in combination with asecond therapeutic agent, the dose of each compound can be either thesame as or differ from that when the compound is used alone. Appropriatedoses will be readily appreciated by those skilled in the art.

The term “administration” and variants thereof (e.g., “administering” acompound) in reference to a compound as described herein meansintroducing the compound or a prodrug of the compound into the system ofthe animal in need of treatment. When a compound as described herein orprodrug thereof is provided in combination with one or more other activeagents (e.g., a cytotoxic agent, etc.), “administration” and itsvariants are each understood to include concurrent and sequentialintroduction of the compound or prodrug thereof and other agents.

In vivo application of the disclosed compounds, and compositionscontaining them, can be accomplished by any suitable method andtechnique presently or prospectively known to those skilled in the art.For example, the disclosed compounds can be formulated in aphysiologically- or pharmaceutically-acceptable form and administered byany suitable route known in the art including, for example, oral, nasal,rectal, topical, and parenteral routes of administration. As usedherein, the term parenteral includes subcutaneous, intradermal,intravenous, intramuscular, intraperitoneal, and intrasternaladministration, such as by injection. Administration of the disclosedcompounds or compositions can be a single administration, or atcontinuous or distinct intervals as can be readily determined by aperson skilled in the art.

The compounds disclosed herein, and compositions comprising them, canalso be administered utilizing liposome technology, slow releasecapsules, implantable pumps, and biodegradable containers. Thesedelivery methods can, advantageously, provide a uniform dosage over anextended period of time. The compounds can also be administered in theirsalt derivative forms or crystalline forms.

The compounds disclosed herein can be formulated according to knownmethods for preparing pharmaceutically acceptable compositions.Formulations are described in detail in a number of sources which arewell known and readily available to those skilled in the art. Forexample, Remington's Pharmaceutical Science by E. W. Martin (1995)describes formulations that can be used in connection with the disclosedmethods. In general, the compounds disclosed herein can be formulatedsuch that an effective amount of the compound is combined with asuitable carrier in order to facilitate effective administration of thecompound. The compositions used can also be in a variety of forms. Theseinclude, for example, solid, semi-solid, and liquid dosage forms, suchas tablets, pills, powders, liquid solutions or suspension,suppositories, injectable and infusible solutions, and sprays. Thepreferred form depends on the intended mode of administration andtherapeutic application. The compositions also preferably includeconventional pharmaceutically-acceptable carriers and diluents which areknown to those skilled in the art. Examples of carriers or diluents foruse with the compounds include ethanol, dimethyl sulfoxide, glycerol,alumina, starch, saline, and equivalent carriers and diluents. Toprovide for the administration of such dosages for the desiredtherapeutic treatment, compositions disclosed herein can advantageouslycomprise between about 0.1% and 99%, and especially, 1 and 15% by weightof the total of one or more of the subject compounds based on the weightof the total composition including carrier or diluent.

Formulations suitable for administration include, for example, aqueoussterile injection solutions, which can contain antioxidants, buffers,bacteriostats, and solutes that render the formulation isotonic with theblood of the intended recipient; and aqueous and nonaqueous sterilesuspensions, which can include suspending agents and thickening agents.The formulations can be presented in unit-dose or multi-dose containers,for example sealed ampoules and vials, and can be stored in a freezedried (lyophilized) condition requiring only the condition of thesterile liquid carrier, for example, water for injections, prior to use.Extemporaneous injection solutions and suspensions can be prepared fromsterile powder, granules, tablets, etc. It should be understood that inaddition to the ingredients particularly mentioned above, thecompositions disclosed herein can include other agents conventional inthe art having regard to the type of formulation in question.

Compounds disclosed herein, and compositions comprising them, can bedelivered to a cell either through direct contact with the cell or via acarrier means. Carrier means for delivering compounds and compositionsto cells are known in the art and include, for example, encapsulatingthe composition in a liposome moiety. Another means for delivery ofcompounds and compositions disclosed herein to a cell comprisesattaching the compounds to a protein or nucleic acid that is targetedfor delivery to the target cell. U.S. Pat. No. 6,960,648 and U.S.Application Publication Nos. 2003/0032594 and 2002/0120100 discloseamino acid sequences that can be coupled to another composition and thatallows the composition to be translocated across biological membranes.U.S. Application Publication No. 2002/0035243 also describescompositions for transporting biological moieties across cell membranesfor intracellular delivery. Compounds can also be incorporated intopolymers, examples of which include poly (D-L lactide-co-glycolide)polymer for intracranial tumors; poly[bis(p-carboxyphenoxy)propane:sebacic acid] in a 20:80 molar ratio (as used in GLIADEL);chondroitin; chitin; and chitosan.

For the treatment of oncological disorders, the compounds disclosedherein can be administered to a patient in need of treatment incombination with other antitumor or anticancer substances and/or withradiation and/or photodynamic therapy and/or with surgical treatment toremove a tumor. These other substances or treatments can be given at thesame as or at different times from the compounds disclosed herein. Forexample, the compounds disclosed herein can be used in combination withmitotic inhibitors such as taxol or vinblastine, alkylating agents suchas cyclophosamide or ifosfamide, antimetabolites such as 5-fluorouracilor hydroxyurea, DNA intercalators such as adriamycin or bleomycin,topoisomerase inhibitors such as etoposide or camptothecin,antiangiogenic agents such as angiostatin, antiestrogens such astamoxifen, and/or other anti-cancer drugs or antibodies, such as, forexample, GLEEVEC (Novartis Pharmaceuticals Corporation) and HERCEPTIN(Genentech, Inc.), respectively.

Many tumors and cancers have viral genome present in the tumor or cancercells. For example, Epstein-Barr Virus (EBV) is associated with a numberof mammalian malignancies. The compounds disclosed herein can also beused alone or in combination with anticancer or antiviral agents, suchas ganciclovir, azidothymidine (AZT), lamivudine (3TC), etc., to treatpatients infected with a virus that can cause cellular transformationand/or to treat patients having a tumor or cancer that is associatedwith the presence of viral genome in the cells. The compounds disclosedherein can also be used in combination with viral based treatments ofoncologic disease. For example, the compounds can be used with mutantherpes simplex virus in the treatment of non-small cell lung cancer(Toyoizumi, et al., “Combined therapy with chemotherapeutic agents andherpes simplex virus type IICP34.5 mutant (HSV-1716) in human non-smallcell lung cancer,” Human Gene Therapy, 1999, 10(18):17).

Therapeutic application of compounds and/or compositions containing themcan be accomplished by any suitable therapeutic method and techniquepresently or prospectively known to those skilled in the art. Further,compounds and compositions disclosed herein have use as startingmaterials or intermediates for the preparation of other useful compoundsand compositions.

Compounds and compositions disclosed herein can be locally administeredat one or more anatomical sites, such as sites of unwanted cell growth(such as a tumor site or benign skin growth, e.g., injected or topicallyapplied to the tumor or skin growth), optionally in combination with apharmaceutically acceptable carrier such as an inert diluent. Compoundsand compositions disclosed herein can be systemically administered, suchas intravenously or orally, optionally in combination with apharmaceutically acceptable carrier such as an inert diluent, or anassimilable edible carrier for oral delivery. They can be enclosed inhard or soft shell gelatin capsules, can be compressed into tablets, orcan be incorporated directly with the food of the patient's diet. Fororal therapeutic administration, the active compound can be combinedwith one or more excipients and used in the form of ingestible tablets,buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers,aerosol sprays, and the like.

The tablets, troches, pills, capsules, and the like can also contain thefollowing: binders such as gum tragacanth, acacia, corn starch orgelatin; excipients such as dicalcium phosphate; a disintegrating agentsuch as corn starch, potato starch, alginic acid and the like; alubricant such as magnesium stearate; and a sweetening agent such assucrose, fructose, lactose or aspartame or a flavoring agent such aspeppermint, oil of wintergreen, or cherry flavoring can be added. Whenthe unit dosage form is a capsule, it can contain, in addition tomaterials of the above type, a liquid carrier, such as a vegetable oilor a polyethylene glycol. Various other materials can be present ascoatings or to otherwise modify the physical form of the solid unitdosage form. For instance, tablets, pills, or capsules can be coatedwith gelatin, wax, shellac, or sugar and the like. A syrup or elixir cancontain the active compound, sucrose or fructose as a sweetening agent,methyl and propylparabens as preservatives, a dye and flavoring such ascherry or orange flavor. Of course, any material used in preparing anyunit dosage form should be pharmaceutically acceptable and substantiallynon-toxic in the amounts employed. In addition, the active compound canbe incorporated into sustained-release preparations and devices.

Compounds and compositions disclosed herein, including pharmaceuticallyacceptable salts, hydrates, or analogs thereof, can be administeredintravenously, intramuscularly, or intraperitoneally by infusion orinjection. Solutions of the active agent or its salts can be prepared inwater, optionally mixed with a nontoxic surfactant. Dispersions can alsobe prepared in glycerol, liquid polyethylene glycols, triacetin, andmixtures thereof and in oils. Under ordinary conditions of storage anduse, these preparations can contain a preservative to prevent the growthof microorganisms.

The pharmaceutical dosage forms suitable for injection or infusion caninclude sterile aqueous solutions or dispersions or sterile powderscomprising the active ingredient, which are adapted for theextemporaneous preparation of sterile injectable or infusible solutionsor dispersions, optionally encapsulated in liposomes. The ultimatedosage form should be sterile, fluid, and stable under the conditions ofmanufacture and storage. The liquid carrier or vehicle can be a solventor liquid dispersion medium comprising, for example, water, ethanol, apolyol (for example, glycerol, propylene glycol, liquid polyethyleneglycols, and the like), vegetable oils, nontoxic glyceryl esters, andsuitable mixtures thereof. The proper fluidity can be maintained, forexample, by the formation of liposomes, by the maintenance of therequired particle size in the case of dispersions or by the use ofsurfactants. Optionally, the prevention of the action of microorganismscan be brought about by various other antibacterial and antifungalagents, for example, parabens, chlorobutanol, phenol, sorbic acid,thimerosal, and the like. In many cases, it will be preferable toinclude isotonic agents, for example, sugars, buffers or sodiumchloride. Prolonged absorption of the injectable compositions can bebrought about by the inclusion of agents that delay absorption, forexample, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating a compoundand/or agent disclosed herein in the required amount in the appropriatesolvent with various other ingredients enumerated above, as required,followed by filter sterilization. In the case of sterile powders for thepreparation of sterile injectable solutions, the preferred methods ofpreparation are vacuum drying and the freeze drying techniques, whichyield a powder of the active ingredient plus any additional desiredingredient present in the previously sterile-filtered solutions.

For topical administration, compounds and agents disclosed herein can beapplied in as a liquid or solid. However, it will generally be desirableto administer them topically to the skin as compositions, in combinationwith a dermatologically acceptable carrier, which can be a solid or aliquid. Compounds and agents and compositions disclosed herein can beapplied topically to a subject's skin to reduce the size (and caninclude complete removal) of malignant or benign growths, or to treat aninfection site. Compounds and agents disclosed herein can be applieddirectly to the growth or infection site. Preferably, the compounds andagents are applied to the growth or infection site in a formulation suchas an ointment, cream, lotion, solution, tincture, or the like. Drugdelivery systems for delivery of pharmacological substances to dermallesions can also be used, such as that described in U.S. Pat. No.5,167,649.

Useful solid carriers include finely divided solids such as talc, clay,microcrystalline cellulose, silica, alumina and the like. Useful liquidcarriers include water, alcohols or glycols or water-alcohol/glycolblends, in which the compounds can be dissolved or dispersed ateffective levels, optionally with the aid of non-toxic surfactants.Adjuvants such as fragrances and additional antimicrobial agents can beadded to optimize the properties for a given use. The resultant liquidcompositions can be applied from absorbent pads, used to impregnatebandages and other dressings, or sprayed onto the affected area usingpump-type or aerosol sprayers, for example.

Thickeners such as synthetic polymers, fatty acids, fatty acid salts andesters, fatty alcohols, modified celluloses or modified mineralmaterials can also be employed with liquid carriers to form spreadablepastes, gels, ointments, soaps, and the like, for application directlyto the skin of the user. Examples of useful dermatological compositionswhich can be used to deliver a compound to the skin are disclosed inU.S. Pat. Nos. 4,608,392; 4,992,478; 4,559,157; and 4,820,508.

Useful dosages of the compounds and agents and pharmaceuticalcompositions disclosed herein can be determined by comparing their invitro activity, and in vivo activity in animal models. Methods for theextrapolation of effective dosages in mice, and other animals, to humansare known to the art; for example, see U.S. Pat. No. 4,938,949.

Also disclosed are pharmaceutical compositions that comprise a compounddisclosed herein in combination with a pharmaceutically acceptablecarrier. Pharmaceutical compositions adapted for oral, topical orparenteral administration, comprising an amount of a compound constitutea preferred aspect. The dose administered to a patient, particularly ahuman, should be sufficient to achieve a therapeutic response in thepatient over a reasonable time frame, without lethal toxicity, andpreferably causing no more than an acceptable level of side effects ormorbidity. One skilled in the art will recognize that dosage will dependupon a variety of factors including the condition (health) of thesubject, the body weight of the subject, kind of concurrent treatment,if any, frequency of treatment, therapeutic ratio, as well as theseverity and stage of the pathological condition.

For the treatment of oncological disorders, compounds and agents andcompositions disclosed herein can be administered to a patient in needof treatment prior to, subsequent to, or in combination with otherantitumor or anticancer agents or substances (e.g., chemotherapeuticagents, immunotherapeutic agents, radiotherapeutic agents, cytotoxicagents, etc.) and/or with radiation therapy and/or with surgicaltreatment to remove a tumor. For example, compounds and agents andcompositions disclosed herein can be used in methods of treating cancerwherein the patient is to be treated or is or has been treated withmitotic inhibitors such as taxol or vinblastine, alkylating agents suchas cyclophosamide or ifosfamide, antimetabolites such as 5-fluorouracilor hydroxyurea, DNA intercalators such as adriamycin or bleomycin,topoisomerase inhibitors such as etoposide or camptothecin,antiangiogenic agents such as angiostatin, antiestrogens such astamoxifen, and/or other anti-cancer drugs or antibodies, such as, forexample, GLEEVEC (Novartis Pharmaceuticals Corporation; East Hanover,NJ) and HERCEPTIN (Genentech, Inc.; South San Francisco, CA),respectively. These other substances or radiation treatments can begiven at the same as or at different times from the compounds disclosedherein. Examples of other suitable chemotherapeutic agents include, butare not limited to, altretamine, bleomycin, bortezomib (VELCADE),busulphan, calcium folinate, capecitabine, carboplatin, carmustine,chlorambucil, cisplatin, cladribine, crisantaspase, cyclophosphamide,cytarabine, dacarbazine, dactinomycin, daunorubicin, docetaxel,doxorubicin, epirubicin, etoposide, fludarabine, fluorouracil, gefitinib(IRESSA), gemcitabine, hydroxyurea, idarubicin, ifosfamide, imatinib(GLEEVEC), irinotecan, liposomal doxorubicin, lomustine, melphalan,mercaptopurine, methotrexate, mitomycin, mitoxantrone, oxaliplatin,paclitaxel, pentostatin, procarbazine, raltitrexed, streptozocin,tegafur-uracil, temozolomide, thiotepa, tioguanine/thioguanine,topotecan, treosulfan, vinblastine, vincristine, vindesine, vinorelbine.In an exemplified embodiment, the chemotherapeutic agent is melphalan.Examples of suitable immunotherapeutic agents include, but are notlimited to, alemtuzumab, cetuximab (ERBITUX), gemtuzumab, iodine 131tositumomab, rituximab, trastuzamab (HERCEPTIN). Cytotoxic agentsinclude, for example, radioactive isotopes (e.g., I¹³¹, I¹²⁵, Y⁹⁰, P³²,etc.), and toxins of bacterial, fungal, plant, or animal origin (e.g.,ricin, botulinum toxin, anthrax toxin, aflatoxin, jellyfish venoms(e.g., box jellyfish, etc.) Also disclosed are methods for treating anoncological disorder comprising administering an effective amount of acompound and/or agent disclosed herein prior to, subsequent to, and/orin combination with administration of a chemotherapeutic agent, animmunotherapeutic agent, a radiotherapeutic agent, or radiotherapy.

Kits

Kits for practicing the methods described herein are further provided.By “kit” is intended any manufacture (e.g., a package or a container)comprising at least one reagent, e.g., anyone of the compounds describedin Table 1. The kit can be promoted, distributed, or sold as a unit forperforming the methods described herein. Additionally, the kits cancontain a package insert describing the kit and methods for its use. Anyor all of the kit reagents can be provided within containers thatprotect them from the external environment, such as in sealed containersor pouches.

To provide for the administration of such dosages for the desiredtherapeutic treatment, in some embodiments, pharmaceutical compositionsdisclosed herein can comprise between about 0.1% and 45%, andespecially, 1 and 15%, by weight of the total of one or more of thecompounds based on the weight of the total composition including carrieror diluents. Illustratively, dosage levels of the administered activeingredients can be: intravenous, 0.01 to about 20 mg/kg;intraperitoneal, 0.01 to about 100 mg/kg; subcutaneous, 0.01 to about100 mg/kg; intramuscular, 0.01 to about 100 mg/kg; orally 0.01 to about200 mg/kg, and preferably about 1 to 100 mg/kg; intranasal instillation,0.01 to about 20 mg/kg; and aerosol, 0.01 to about 20 mg/kg of animal(body) weight.

Also disclosed are kits that comprise a composition comprising acompound disclosed herein in one or more containers. The disclosed kitscan optionally include pharmaceutically acceptable carriers and/ordiluents. In one embodiment, a kit includes one or more othercomponents, adjuncts, or adjuvants as described herein. In anotherembodiment, a kit includes one or more anti-cancer agents, such as thoseagents described herein. In one embodiment, a kit includes instructionsor packaging materials that describe how to administer a compound orcomposition of the kit. Containers of the kit can be of any suitablematerial, e.g., glass, plastic, metal, etc., and of any suitable size,shape, or configuration. In one embodiment, a compound and/or agentdisclosed herein is provided in the kit as a solid, such as a tablet,pill, or powder form. In another embodiment, a compound and/or agentdisclosed herein is provided in the kit as a liquid or solution. In oneembodiment, the kit comprises an ampoule or syringe containing acompound and/or agent disclosed herein in liquid or solution form.

EXAMPLES

The following examples are put forth so as to provide those of ordinaryskill in the art with a complete disclosure and description of how thecompounds, compositions, articles, devices and/or methods claimed hereinare made and evaluated, and are intended to be purely exemplary of theinvention and are not intended to limit the scope of what the inventorsregard as their invention. Efforts have been made to ensure accuracywith respect to numbers (e.g., amounts, temperature, etc.), but someerrors and deviations should be accounted for. Unless indicatedotherwise, parts are parts by weight, temperature is in ° C. or is atambient temperature, and pressure is at or near atmospheric.

Compound Synthesis

The compounds disclosed herein can be prepared by the following generalroute:

For example, the compounds can be prepared by a route disclosed inWO2015/021149 and WO 2017/023899, each of which is incorporated byreference herein for its synthetic techniques and characterizationassays.

Representative syntheses of intermediates as may be used in the firststep of the above route are provided below:

Intermediate 1

2,5-Dichloro-N-phenethylpyrimidin-4-amine (Int-1): To a solution ofphenylethylamine (0.628 g, 5.180 mmol) in MeOH (10 mL) under Argon at 0°C. was added Et₃N (0.76 mL, 5.453 mmol). The reaction mixture wasstirred at 0° C. for 10 min., followed by adding solution of2,4,5-trichloropyrimidine (1.000 g, 5.453 mmol) in MeOH slowly. Thereaction mixture was warmed up to r.t. after addition and stirred for 2h. The solvent was removed and the resulting residue was diluted withEtOAc (50 mL) and washed with water (25 mL), then brine (20 mL). Theorganic layer was dried (Na₂SO₄), filtered and concentrated to obtainthe title compound as an orange liquid (1.290 g, 92.8%). ¹H NMR (400MHz, CDCl₃): δ 7.98 (s, 1H), 7.35-7.21 (m, 5H), 5.57 (brs, 1H),3.80-3.75 (m, 2H), 2.95-2.92 (t, J=6.8 Hz, 2H).

Intermediate 2

2,5-Dichloro-N-(2-chloro-6-fluorophenethyl)pyrimidin-4-amine (Int-2):This was prepared in the same way as Int-1 using2-fluoro-6-chlorophenylethylamine (0.984 g, 5.180 mmol) to provide thetitle compound as a white powder (0.972 g, 59%). ¹H NMR (400 MHz,CD3OD): δ 7.98 (s, 1H), 7.20-7.18 (m, 2H), 7.03-6.99 (m, 1H), 3.775 (t,J=6.8 HZ, 2H), 3.14 (dt, J=2.0 Hz, 6.4 Hz, 2H).

The compositions and methods of the appended claims are not limited inscope by the specific compositions and methods described herein, whichare intended as illustrations of a few aspects of the claims and anycompositions and methods that are functionally equivalent are intendedto fall within the scope of the claims. Various modifications of thecompositions and methods in addition to those shown and described hereinare intended to fall within the scope of the appended claims. Further,while only certain representative compositions and method stepsdisclosed herein are specifically described, other combinations of thecompositions and method steps also are intended to fall within the scopeof the appended claims, even if not specifically recited. Thus, acombination of steps, elements, components, or constituents may beexplicitly mentioned herein; however, other combinations of steps,elements, components, and constituents are included, even though notexplicitly stated.

The term “comprising” and variations thereof as used herein is usedsynonymously with the term “including” and variations thereof and areopen, non-limiting terms. Although the terms “comprising” and“including” have been used herein to describe various embodiments, theterms “consisting essentially of” and “consisting of” can be used inplace of “comprising” and “including” to provide for more specificembodiments of the invention and are also disclosed. Other than in theexamples, or where otherwise noted, all numbers expressing quantities ofingredients, reaction conditions, and so forth used in the specificationand claims are to be understood at the very least, and not as an attemptto limit the application of the doctrine of equivalents to the scope ofthe claims, to be construed in light of the number of significant digitsand ordinary rounding approaches.

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof; wherein: R¹ is selectedfrom C₁-C₆ alkyl, C₃-C₆ cycloalkyl, and aryl; R² is selected fromhydrogen and halo; R³ is selected from C₁-C₆ alkyl and halo; R⁴ isselected from C₁-C₆ alkoxy, aryloxy, and C₃-C₆ cycloalkyoxy; R⁵ is C₁-C₆alkoxy, C₃-C₆ cycloalkoxy, C₁-C₆ alkyl, halo, cyano, and hydroxy; L isselected from a bond, C₁-C₃ alkyl, or —O—(C₁-C₃ alkyl)-; R⁶ is selectedfrom optionally substituted C₄-C₈ heterocycle or optionally substitutedheteroaryl; and m is 0 or
 1. 2. A compound of Formula II:

or a pharmaceutically acceptable salt thereof; wherein: R¹ is selectedfrom C₁-C₆ alkyl, C₃-C₆ cycloalkyl, and aryl; R³ is selected from C₁-C₆alkyl and halo; L is selected from a bond, C₁-C₃ alkyl, or —O—(C₁-C₃alkyl)-; R⁶ is selected from optionally substituted C₄-C₈ heterocycle oroptionally substituted heteroaryl; R⁷ is selected from C₁-C₆ alkoxy,C₃-C₆ cycloalkoxy, C₁-C₆ alkyl, halo, cyano, and hydroxy; and n is 0, 1,or
 2. 3. A compound selected from:

or a pharmaceutically acceptable salt thereof.
 4. (canceled) 5.(canceled)
 6. A pharmaceutical composition comprising a compound ofclaim 1, or a pharmaceutically acceptable salt thereof, and apharmaceutically acceptable carrier.
 7. A method of treating a cancer ina subject in need thereof comprising administering to the subject atherapeutically effective amount of a compound of claim 1, or apharmaceutically acceptable salt thereof.
 8. The method of claim 7,further comprising administering an additional therapeutic agent.
 9. Themethod of claim 8, wherein the additional therapeutic agent comprises ananti-cancer agent or an anti-inflammatory agent.
 10. The method of claim7, further comprising administering an effective amount of ionizingradiation to the subject.
 11. A method of killing a tumor cellcomprising contacting the tumor cell with an effective amount of acompound of claim 1, or a pharmaceutically acceptable salt thereof. 12.A pharmaceutical composition comprising a compound of claim 2, or apharmaceutically acceptable salt thereof, and a pharmaceuticallyacceptable carrier.
 13. A method of treating a cancer in a subject inneed thereof comprising administering to the subject a therapeuticallyeffective amount of a compound of claim 2, or a pharmaceuticallyacceptable salt thereof.
 14. The method of claim 13, further comprisingadministering an additional therapeutic agent.
 15. The method of claim14, wherein the additional therapeutic agent comprises an anti-canceragent or an anti-inflammatory agent.
 16. The method of claim 13, furthercomprising administering an effective amount of ionizing radiation tothe subject.
 17. A method of killing a tumor cell comprising contactingthe tumor cell with an effective amount of a compound of claim 2, or apharmaceutically acceptable salt thereof.
 18. A pharmaceuticalcomposition comprising a compound of claim 3, or a pharmaceuticallyacceptable salt thereof, and a pharmaceutically acceptable carrier. 19.A method of treating a cancer in a subject in need thereof comprisingadministering to the subject a therapeutically effective amount of acompound of claim 3, or a pharmaceutically acceptable salt thereof. 20.The method of claim 19, further comprising administering an additionaltherapeutic agent.
 21. The method of claim 20, wherein the additionaltherapeutic agent comprises an anti-cancer agent or an anti-inflammatoryagent.
 22. The method of claim 19, further comprising administering aneffective amount of ionizing radiation to the subject.
 23. A method ofkilling a tumor cell comprising contacting the tumor cell with aneffective amount of a compound of claim 3, or a pharmaceuticallyacceptable salt thereof.